OBJECTIVE: P-selectin (PSEL) and its ligand, P-selectin glycoprotein ligand-1 (PSGL-1), play key roles in both the inflammatory response and the atherosclerotic process, but there are conflicting results regarding the affect of PSEL and PSGL-1 gene variation on risk for cardiovascular and cerebrovascular disease. We tested the association of four PSEL and two PSGL-1 polymorphisms with incident coronary heart disease (CHD) and ischemic stroke among 13,875 participants in the prospective Atherosclerosis Risk in Communities (ARIC) study. We also tested common haplotypes in the PSEL and PSGL-1 genes to assess associations with incident CHD and ischemic stroke. METHODS AND RESULTS: Incident ischemic stroke and CHD were identified through annual telephone calls and hospital and death certificate surveillance. Five hundred and twenty-five validated ischemic stroke and 1654 CHD events were identified. Allele frequencies for all PSEL and PSGL-1 polymorphisms were markedly different between whites and African Americans; therefore, all analyses were performed race-specific. Independent analyses showed the PSEL 290NN genotype to be a significant predictor of CHD in whites (HRR 1.30, 95%CI 1.00-1.70, P=0.05). PSGL-1 genotypes carrying the 62I allele were significantly protective for incident CHD (HRR 0.53, 95%CI 0.31-0.92, P=0.02) and ischemic stroke (HRR 0.73, 95%CI 0.55-0.97, P=0.03) in African Americans. Haplotype analyses showed the PSEL NNVP haplotype to be a significant predictor of incident CHD in whites (HRR 2.09, 95%CI 1.23-3.55, P=0.006). No significant haplotype findings were observed in African Americans. CONCLUSIONS: PSEL S290N, in single polymorphism analysis and in the haplotypic background with T715P, was associated with increased risk of incident CHD in whites. The PSGL-1 M62I polymorphism was associated with decreased risk of both incident CHD and stroke in African Americans. These findings illustrate the complex relationship between genetic variation and disease in different racial groups.
OBJECTIVE:P-selectin (PSEL) and its ligand, P-selectin glycoprotein ligand-1 (PSGL-1), play key roles in both the inflammatory response and the atherosclerotic process, but there are conflicting results regarding the affect of PSEL and PSGL-1 gene variation on risk for cardiovascular and cerebrovascular disease. We tested the association of four PSEL and two PSGL-1 polymorphisms with incident coronary heart disease (CHD) and ischemic stroke among 13,875 participants in the prospective Atherosclerosis Risk in Communities (ARIC) study. We also tested common haplotypes in the PSEL and PSGL-1 genes to assess associations with incident CHD and ischemic stroke. METHODS AND RESULTS: Incident ischemic stroke and CHD were identified through annual telephone calls and hospital and death certificate surveillance. Five hundred and twenty-five validated ischemic stroke and 1654 CHD events were identified. Allele frequencies for all PSEL and PSGL-1 polymorphisms were markedly different between whites and African Americans; therefore, all analyses were performed race-specific. Independent analyses showed the PSEL 290NN genotype to be a significant predictor of CHD in whites (HRR 1.30, 95%CI 1.00-1.70, P=0.05). PSGL-1 genotypes carrying the 62I allele were significantly protective for incident CHD (HRR 0.53, 95%CI 0.31-0.92, P=0.02) and ischemic stroke (HRR 0.73, 95%CI 0.55-0.97, P=0.03) in African Americans. Haplotype analyses showed the PSEL NNVP haplotype to be a significant predictor of incident CHD in whites (HRR 2.09, 95%CI 1.23-3.55, P=0.006). No significant haplotype findings were observed in African Americans. CONCLUSIONS:PSELS290N, in single polymorphism analysis and in the haplotypic background with T715P, was associated with increased risk of incident CHD in whites. The PSGL-1M62I polymorphism was associated with decreased risk of both incident CHD and stroke in African Americans. These findings illustrate the complex relationship between genetic variation and disease in different racial groups.
Authors: S C Barbaux; S Blankenberg; H J Rupprecht; C Francomme; C Bickel; G Hafner; V Nicaud; J Meyer; F Cambien; L Tiret Journal: Arterioscler Thromb Vasc Biol Date: 2001-10 Impact factor: 8.311
Authors: M L Lozano; R González-Conejero; J Corral; J Rivera; J A Iniesta; C Martinez; V Vicente Journal: Br J Haematol Date: 2001-12 Impact factor: 6.998
Authors: J William Phillips; Kurt G Barringhaus; John M Sanders; Sean E Hesselbacher; Ann C Czarnik; David Manka; Dietmar Vestweber; Klaus Ley; Ian J Sarembock Journal: Circulation Date: 2003-04-21 Impact factor: 29.690
Authors: F Kee; C Morrison; A E Evans; E McCrum; D McMaster; J Dallongeville; V Nicaud; O Poirier; F Cambien Journal: Heart Date: 2000-11 Impact factor: 5.994
Authors: M Fumagalli; M Fracassetti; R Cagliani; D Forni; U Pozzoli; G P Comi; F Marini; N Bresolin; M Clerici; M Sironi Journal: Heredity (Edinb) Date: 2012-05-02 Impact factor: 3.821
Authors: Kelly A Volcik; Diane Catellier; Aaron R Folsom; Nena Matijevic; Bruce Wasserman; Eric Boerwinkle Journal: Clin Chem Date: 2009-04-24 Impact factor: 8.327